EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MGMT methylation and its prognostic significance in inoperable IDH-wildtype glioblastoma: the MGMT-GBM study

Prajwal Ghimire, Ahmad Kamaludin, Berta F Palau, Jose P Lavrador, Richard Gullan, Francesco Vergani, Ranjeev Bhangoo, Keyoumars Ashkan

Acta Neurochirurgica · 05.10.2024 · 166 (1)

DOI: 10.1007/s00701-024-06300-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Neurochirurgica, online erschienen am 05.10.2024. Verfasst von Prajwal Ghimire und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK. prajwal.1.ghimire@kcl.ac.uk. Hauptthemen laut MEDLINE: Glioblastoma, DNA Modification Methylases, Tumor Suppressor Proteins, Biomarkers, Tumor. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The methylation of the O6-Methylguanine-DNA Methyltransferase (MGMT) promoter is a valid biomarker for predicting response to therapy with alkylating agents and, independently, prognosis in IDH-wildtype(IDH-w) glioblastoma. We aim to study the impact of its methylation in overall survival of the unresectable IDH-w glioblastoma undergoing biopsy and systemic treatment.

Methods

We collected six-year retrospective (2017–2023) data at a quaternary neurosurgery center for patients undergoing biopsy as the only surgical procedure for an unresectable IDH wildtype glioblastoma. Data was collected from patient records including neuro-oncology multidisciplinary team meeting (MDT) documentation. Patients were grouped into categories according to different types of treatment received after biopsy (no treatment, chemotherapy (CT), radiotherapy (RT), chemoradiotherapy (CRT), chemoradiotherapy with adjuvant temozolomide (CRT with adjuvant TMZ), EORTC-NCIC protocol followed by second line treatment) and according to methylation status (unmethylated (< 5%), borderline methylated (5–15%) and strongly methylated (> 15%)). Survival analysis was performed.

Results

166 glioblastoma IDH wildtype patients were included in the study with mean age of 62.5 years (M: F = 1.5: 1). 70 (49.3%) patients had unmethylated MGMT status (< 5%), 29 (20.4%) patients had borderline methylated MGMT status (5–15%) and 43 (30.2%) patients had methylated MGMT status (> 15%). 36 (25.3%) patients did not receive any treatment post biopsy, 13 (9.1%) received CT only, 27 (19%) RT only, 12 (8.4%) CRT, 33 (23.2%) CRT with adjuvant TMZ, whereas 21 (14.7%) received EORTC-NCIC protocol along with second line treatment. In biopsy only group, there was no notable difference in survival outcomes among the different methylation statuses. For biopsy and any-other-form-of-treatment methylated groups showed a distinct trend of better survival compared to the borderline or unmethylated groups. Overall, methylated patients had better survival as compared to unmethylated or borderline groups.

Conclusion

Methylated MGMT status are predictors for better overall survival in unresectable IDH wildtype glioblastoma patients undergoing biopsy and treatment regardless of the treatment modality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaDNA Modification MethylasesTumor Suppressor ProteinsBiomarkers, TumorRetrospective StudiesIsocitrate DehydrogenaseDNA MethylationBiopsyGene Expression Regulation, NeoplasticAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyChemotherapy, AdjuvantPromoter Regions, GeneticKaplan-Meier EstimateHumansMaleFemaleAdultMiddle AgedAgedPrognosisDNA Repair Enzymes

Stichwörter der Autor:innen

IDH-wildtype glioblastomaMGMTPredictive biomarkerSurvival

Substanzen

Isocitrate DehydrogenaseDNA Modification MethylasesTumor Suppressor ProteinsBiomarkers, TumorMGMT protein, humanDNA Repair Enzymes

Autor:innen und Institutionen

  • School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK. prajwal.1.ghimire@kcl.ac.uk.
  • Department of Neurosurgery, King's College Hospital, London, UK. prajwal.1.ghimire@kcl.ac.uk.
  • Department of Neurosurgery, King's College Hospital, London, UK.
  • School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK.

Zitieren

APA

Ghimire, P., Kamaludin, A., Palau, B. F., Lavrador, J. P., Gullan, R., Vergani, F., Bhangoo, R., & Ashkan, K. (2024). MGMT methylation and its prognostic significance in inoperable IDH-wildtype glioblastoma: the MGMT-GBM study. Acta Neurochirurgica, 166(1). https://doi.org/10.1007/s00701-024-06300-x

Vancouver

Ghimire P, Kamaludin A, Palau BF, Lavrador JP, Gullan R, Vergani F, et al. MGMT methylation and its prognostic significance in inoperable IDH-wildtype glioblastoma: the MGMT-GBM study. Acta Neurochirurgica. 2024;166(1). doi:10.1007/s00701-024-06300-x

BibTeX
@article{Ghimire2024,
  author = {Ghimire, Prajwal and Kamaludin, Ahmad and Palau, Berta F and Lavrador, Jose P and Gullan, Richard and Vergani, Francesco and Bhangoo, Ranjeev and Ashkan, Keyoumars},
  title = {MGMT methylation and its prognostic significance in inoperable IDH-wildtype glioblastoma: the MGMT-GBM study},
  journal = {Acta Neurochirurgica},
  year = {2024},
  volume = {166},
  number = {1},
  doi = {10.1007/s00701-024-06300-x}
}
Kostenlos starten →